Jaime R Merchan
Jaime R Merchan
Associate Professor of Medicine, University of Miami Miller School of Medicine
Verified email at
Cited by
Cited by
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia
SE Maynard, JY Min, J Merchan, KH Lim, J Li, S Mondal, TA Libermann, ...
The Journal of clinical investigation 111 (5), 649-658, 2003
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ...
New England Journal of Medicine 369 (8), 722-731, 2013
Sunitinib in patients with metastatic renal cell carcinoma
RJ Motzer, BI Rini, RM Bukowski, BD Curti, DJ George, GR Hudes, ...
Jama 295 (21), 2516-2524, 2006
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma
R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ...
New England Journal of Medicine 384 (14), 1289-1300, 2021
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
PJ Hosein, J Macintyre, C Kawamura, JC Maldonado, V Ernani, ...
BMC cancer 12 (1), 1-7, 2012
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials
BC Leibovich, JC Cheville, CM Lohse, H Zincke, I Frank, ED Kwon, ...
The Journal of urology 174 (5), 1759-1763, 2005
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
BA Wilky, MM Trucco, TK Subhawong, V Florou, W Park, D Kwon, ...
The lancet oncology 20 (6), 837-848, 2019
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer
PJ Hosein, G de Lima Lopes Jr, VH Pastorini, C Gomez, J Macintyre, ...
American journal of clinical oncology 36 (2), 151-156, 2013
Renal cancer: molecular mechanisms and newer therapeutic options
SA Karumanchi, J Merchan, VP Sukhatme
Current opinion in nephrology and hypertension 11 (1), 37-42, 2002
Antiangiogenic activity of 2-deoxy-D-glucose
JR Merchan, K Kovács, JW Railsback, M Kurtoglu, Y Jing, Y Pińa, N Gao, ...
PloS one 5 (10), e13699, 2010
Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC): results of the COMPARZ trial
R Motzer, TE Hutson, J Reeves, R Hawkins, J Guo, P Nathan, M Staehler, ...
Annals of oncology 23, ixe13, 2012
EUS visualization and direct celiac ganglia neurolysis predicts better pain relief in patients with pancreatic malignancy (with video)
G Ascunce, A Ribeiro, I Reis, C Rocha-Lima, D Sleeman, J Merchan, ...
Gastrointestinal endoscopy 73 (2), 267-274, 2011
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox‐2 inhibition
JR Merchan, DR Jayaram, JG Supko, X He, GJ Bubley, VP Sukhatme
International journal of cancer 113 (3), 490-498, 2005
A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma
SN Markovic, VJ Suman, RA Rao, JN Ingle, JS Kaur, LA Erickson, ...
American journal of clinical oncology 30 (3), 303-309, 2007
Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results
JR Merchan, G Liu, T Fitch, J Picus, R Qin, HC Pitot, W Maples, ...
Journal of Clinical Oncology 25 (18_suppl), 5034-5034, 2007
Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma
G Narayanan, PJ Hosein, IC Beulaygue, T Froud, HJ Scheffer, SR Venkat, ...
Journal of vascular and interventional radiology 28 (3), 342-348, 2017
Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
JE Rosenberg, TW Flaig, TW Friedlander, MI Milowsky, S Srinivas, ...
Journal of Clinical Oncology 38 (6_suppl), 441-441, 2020
A phase 2 pilot trial of low‐dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma
RS Bhatt, J Merchan, R Parker, HK Wu, L Zhang, V Seery, JV Heymach, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2010
Targeted measles virus vector displaying echistatin infects endothelial cells via αvβ3 and leads to tumor regression
LK Hallak, JR Merchan, CM Storgard, JC Loftus, SJ Russell
Cancer research 65 (12), 5292-5300, 2005
Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma
N Dempsey, JC Maldonado, A Loaiza-Bonilla, M Velez, L Carcas, ...
Pancreatology 15 (6), 667-673, 2015
The system can't perform the operation now. Try again later.
Articles 1–20